Save

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

PHASE1PHASE2RECRUITING

This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.

Simpliy with AI

Study details:

This is a phase I/II study to assess the safety and tolerability of APG-115 alone or in combination with pembrolizumab in patients with unresectable or metastatic melanoma, NSCLC, solid tumors with ATM mutation, liposarcoma, urothelial carcinomas, and malignant peripheral nerve sheath tumors (MPNST)The hypothesis is that the current therapy may improve ORR, progression-free survival, and synergistic effect of APG-115 alone or in combination with pembrolizumab in these patients. (n=230, ID: NCT03611868).

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Male or non-pregnant, non-lactating female patients age ≥18 years, an exception for MPNST cohort: adolescents ≥12 years old (who weigh at least 40 kg) is allowed

Measurable disease according to RECIST 1.1. Lesions situated in a previously irradiated area, or an area subject to other loco-regional therapy (e.g., intralesional injections) should be considered non-measurable

ECOG performance status 0-2

Cohort A: Histologically confirmed, unresectable or metastatic melanoma, and refractory or relapse after PD-1 antibody treatment and ineligible for other standard of care therapy per NCCN guideline (previous PD-1/PD-L1 antibody treatment not required for uveal melanoma)

Cohort F: Histologically confirmed, metastatic or unresectable MPNST

Life expectancy ≥ 3 months

Continuance of treatment related toxicities (except alopecia) due to prior radiotherapy or chemotherapy agents or biological therapy (including PD-1/PD-L1 antibodies) must be ≤ grade 1 at the time of dosing

Adequate bone marrow and organ function without continuous supportive treatment

QTcF interval (mean of 3, 1-3 minutes between tests) ≤450 ms in males and ≤470 ms in females

Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan

Tumor tissue must be provided for all subjects for biomarker analysis before treatment with investigational product

Willingness to use contraception by a method that is deemed effective by both male and female patients of childbearing potential and their partners throughout the treatment period and for at least three months following the last dose of study drug

Ability to understand and willingness to sign a written informed consent form.

Exclusion criteria

Any prior systemic MDM2-p53 inhibitor treatment

Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to first dose

Part 2 Cohort A: Prior loco-regional treatment with intralesional therapy (e.g., talimogene laherparepvec) for unresectable or metastatic melanoma in the last 6 weeks prior to start of study treatment

Part 2 Cohort B: Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of trial treatment

Part 2 Cohort E: Known FGFR translocation mutation

Received hormonal and biologic, small molecule targeted therapies or other anti-cancer therapy within 21 days prior to first dose

Radiation or surgery within 14 days prior to first dose, thoracic radiation within 28 days prior to first dose

Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Or has neurologic instability per clinical evaluation due to tumor involvement of the CNS.

Requirement for corticosteroid treatment (with the exception of megestrol and local use of steroid: i.e., topical corticosteroids, inhaled corticosteroids for reactive airway disease, ophthalmic, intraarticular, and intranasal steroids

Concurrent treatment with an investigational agent or device within 21 days prior to the first dose of therapy

Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from 1st dose of study treatment, and patients who have had minor surgery within 14 days from 1st dose of study treatment.

Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry

Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation

Active infection requiring systemic antibiotic/ antifungal medication, and known clinically active viral infection such as hepatitis B or C, HIV infection, or active COVID-19

Has received a live vaccine within 30 days prior to first dose.

Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant

Has previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)

Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study

History of organ transplant requiring use of immunosuppressive medication

A woman of childbearing potential who has a positive urine or serum pregnancy test (within 72 hours) prior to treatment.

Simplify with AI

Eligibility

Age eligible for study : 12 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2018-08-29

Primary completion: 2024-12-30

Study completion finish: 2025-03-30

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT03611868

Intervention or treatment

DRUG: Phase 1b: APG-115+pembrolizumab

Conditions

• Melanoma
• Uveal Melanoma
• Cutaneous Melanoma
• Mucosal Melanoma
• Unresectable or Metastatic Melanoma or Advanced Solid Tumors
• P53 Mutation
• MDM2 Gene Mutation
• Malignant Peripheral Nerve Sheath Tumors (MPNST)

Condition: Melanoma, Uveal Melanoma and more
DRUG: Phase 1b: APG-115+pembrolizumab
South Brisbane, Queensland, Australia and more
Sponsor: Ascentage Pharma Group Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Queensland Children's Hospital

Research sites nearby

Select from list below to view details:

Queensland Children's Hospital
South Brisbane, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Metro South Hospital and Health Services via Princess Alexandra Hospital
Brisbane, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: APG-115+pembrolizumab open label, two-part phase Ib/II single arm dose escalation and dose expansion	DRUG: Phase 1b: APG-115+pembrolizumab dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle. Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: APG-115+pembrolizumab open label, two-part phase Ib/II

single arm dose escalation and dose expansion

DRUG: Phase 1b: APG-115+pembrolizumab

dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Maximum Tolerated Dose	Part I is to assess the safety and tolerability of APG-115 by assessing the dose-limiting toxicity (DLT) of APG-115 in combination with pembrolizumab. End points included: Incidence of DLTs during the first 3 weeks of treatment of each dose cohort; Severity and frequency of any adverse event(s) (AE) and serious adverse event(s) (SAE) based on NCI CTCAE 5.0	21 days
Recommended Phase II Dose	Part I is aimed to generate data to select the recommended Phase II dose	21 days
Overall Response Rate	Phase II is to assess overall response rate of APG-115 as monotherapy and in combination with pembrolizumab defined as the percentage of subjects with a best overall confirmed complete response (CR) or a partial response (PR) at any time as per RECIST 1.1	up to 12 months

Secondary outcome

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors